...
首页> 外文期刊>Microorganisms >Bacterial Endotoxin Testing—Fast Endotoxin Masking Kinetics in the Presence of Lauryldimethylamine Oxide
【24h】

Bacterial Endotoxin Testing—Fast Endotoxin Masking Kinetics in the Presence of Lauryldimethylamine Oxide

机译:细菌内毒素测试 - 在LausDlimethylamine氧化物存在下的快速内毒素掩蔽动力学

获取原文
           

摘要

For release of parenteral drug products, bacterial endotoxin testing is one of a panel of necessary tests. In order to ensure the validity of such tests, various controls are performed, including demonstration of compendial method suitability or method qualification. In addition to compendial suitability testing, quality control (QC) sample hold-time studies are requested by authorities like the Food and Drug Administration (FDA) as described in “Guidance for Industry: Pyrogen and Endotoxins Testing.” It is requested to be determine whether the ability to detect endotoxins can be affected by storage and handling of the sample to be tested. To accomplish these studies, endotoxin is introduced or spiked into the undiluted product and held for a certain period of time in process-representative containers. This time period reflects procedural maximum QC sample hold time from sampling until analysis. Inadequate detection of endotoxin can be caused by adsorption of endotoxin to container surfaces or molecular masking effects, in which the binding sites on the endotoxin molecules are prevented from triggering the enzymatic cascade necessary in the assay, are obscured. The endotoxin may form macromolecular structures, such as sheets or blebs, or the binding sites may otherwise be rendered unavailable due to the sample matrix composition. In either case, the endotoxin assay may yield falsely low results if and when masking occurs. In this work, the QC sample hold times of different in-process controls within the production process of a biopharmaceutical product were analyzed. One out of eight different samples showed a strong masking of endotoxin. Analysis of the sample composition revealed that either kifunensine, mycophenolic acid (MPA), or lauryl-N, N-dimethylamine oxide (LDAO) was responsible for masking. Further analysis clearly identified LDAO as the root cause for masking. A novel one-step mechanism for LDAO-induced endotoxin masking is proposed. The principle is similar to an already-proposed two-step mechanism for endotoxin masking, but the LDAO case combines these two steps: the disturbance of the salt bridges and hydrophobic interactions with LPS in one molecule. These molecular interactions occur quickly when both endotoxin and LDAO are present in the same matrix. Thus, depending on the masking agents, low endotoxin recovery (LER) can occur regardless of the QC sample hold duration.
机译:对于释放肠胃外药品,细菌内毒素检测是必要测试板之一。为了确保这种测试的有效性,执行各种控制,包括展示项方法适用性或方法资格。除了竞选适用性测试外,质量控制(QC)样本持有时间研究由食品和药物管理局(FDA)等当局要求的,如“行业指南:热原和内毒素检测”中所述。要求确定是否可以通过储存和处理要测试的样品的储存和处理来影响探测内毒素的能力。为了完成这些研究,引入内毒素或尖刺到未稀释的产品中,并在工艺代表容器中持有一段时间。此时间段反映了过程最大QC样本保持时间从采样直到分析。内毒素的检测不足可能是由内毒素对容器表面或分子掩蔽作用引起的,其中内毒素分子上的结合位点被防止在测定中触发酶级联。内毒素可以形成大分子结构,例如片材或填充,或者由于样品基质组合物,否则可以使结合位点呈不可用。在任何一种情况下,如果发生掩蔽时,内毒素测定可能会产生错误的低结果。在这项工作中,分析了生物制药产品的生产过程中不同的过程控制的QC样本保持时间。八种不同样品中的一个是内毒素的强烈掩蔽。样品组合物的分析表明,磷酸胺,霉酚酸(MPa)或月桂基-N,N-二甲胺氧化物(LDAO)负责掩蔽。进一步的分析清楚地确定了LDAO作为掩蔽的根本原因。提出了一种新的LDAO诱导的内毒素掩蔽的一步机制。该原理类似于已经提出的内毒素掩蔽的两步机制,但是LDAO病例结合了这两个步骤:盐桥与一个分子中的LPS的疏水相互作用的干扰。当内毒素和LDAO存在于相同的基质中时,这些分子相互作用会很快发生。因此,根据掩模剂,无论QC样品保持持续时间,都会发生低内毒素回收率(LER)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号